Zacks Research Issues Optimistic Forecast for GSK Earnings

GSK plc (NYSE:GSK - Free Report) - Analysts at Zacks Research increased their Q2 2025 earnings per share (EPS) estimates for GSK in a report issued on Wednesday, May 21st. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings per share of $1.08 for the quarter, up from their previous forecast of $1.05. The consensus estimate for GSK's current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK's Q4 2025 earnings at $0.87 EPS, FY2025 earnings at $4.36 EPS, Q3 2026 earnings at $1.42 EPS, Q4 2026 earnings at $1.09 EPS and FY2027 earnings at $4.93 EPS.

Several other research analysts have also commented on GSK. Hsbc Global Res upgraded GSK to a "strong sell" rating in a research report on Monday, April 28th. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, BNP Paribas began coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.58.

GSK Trading Up 1.0%

GSK opened at $38.91 on Friday. GSK has a 52 week low of $31.72 and a 52 week high of $45.77. The business has a fifty day simple moving average of $37.31 and a 200-day simple moving average of $36.01. The firm has a market cap of $80.28 billion, a P/E ratio of 24.47, a P/E/G ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.43 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Kingsview Wealth Management LLC boosted its holdings in GSK by 1.8% in the first quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock valued at $590,000 after purchasing an additional 271 shares during the period. Dorsey & Whitney Trust CO LLC boosted its holdings in GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after purchasing an additional 278 shares during the period. Rehmann Capital Advisory Group boosted its holdings in GSK by 4.6% in the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock valued at $248,000 after purchasing an additional 279 shares during the period. First PREMIER Bank boosted its holdings in GSK by 6.5% in the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock valued at $181,000 after purchasing an additional 286 shares during the period. Finally, Northwest Bank & Trust Co lifted its holdings in GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after buying an additional 289 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a yield of 4.33%. GSK's dividend payout ratio (DPR) is 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.